We do have COVID-19 IgG/IgM Immunoassay rapid tests to fight the pandemic
0

Your Cart is Empty

How SCHISTO-H lurks behind the scenes of global women's health

October 28, 2016

How SCHISTO-H lurks behind the scenes of global women's health

Malaria is the most destructive parasitic illness, by many accounts, but the second most is much less well-known.

Schistosomiasis [shis-tuh-soh-mahy-uh-sis] infects over 250 million people.

It is a common in areas with stagnant water where the where the parasitic flat-worms can enter even unbroken skin and take up residence in a host. The flat worms then produce thousands of eggs per day that can overwhelm the host’s organs. The disease itself is effectively treated with praziquantel but reinfection can occur quickly. This is a disease desperate for a vaccine.

Schistosomiasis is of interest to Maternova because it is particularly harmful to pregnant women and young children as these populations have less developed or compromised immune systems. Repeated infection with schistosomiasis causes anemia and stunted growth. For girls, a specific strain we nickname SCHISTO-H is a threat to the reproductive organs. Furthermore, the scarring and wear and tear caused by SCHISTO-H can also leave girls and women more vulnerable to HIV.

How do you treat schisto? The drug, praziquantel, has been the sole recommended treatment to combat Schistosomiasis and has been around for over 30 years. A concern though, is that this common, effective (and cheap) treatment has not determined to be safe in pregnancy or dosed appropriately for very young children who seem to be much more susceptible to the disease. The [Pediatric Praziquantel Consortium has received nearly $5M from the Japanese GHIT to research a more safe and effective formulation of praziquantel for children](http://www.prnewswire.com/news-releases/pediatric-praziquantel-consortium-awarded-usd49-million-grant-from-global-health-innovative-technology-fund-505453661.html)

A vaccine is in development that has been proven to be effective in mice and is showing promise in water buffalo. Since this disease is spread in stagnant water contaminated with infected feces, it is thought that human infection would be greatly decreased by vaccinating some of the livestock.

Schistosomiasis is in a grouping of the WHO (World Health Organization) classifies as Neglected Tropical Diseases. Much more research is needed in areas of treatment AND vaccine.

Coming soon, information on rapid testing, and more about some exciting Schistosomiasis research from two Rhode Island researchers.

Maternova offers HIV 1/2 rapid test, as well as Schistosomiasis test



Paula McGovern and Meg Wirth


Leave a comment

Comments will be approved before showing up.


Also in The Maternova blog

High-Fidelity Lactation Simulators Hit the Market and Spur More Realistic Teaching on Breast Health and Lactation
High-Fidelity Lactation Simulators Hit the Market and Spur More Realistic Teaching on Breast Health and Lactation

January 03, 2021

Maternova is proud to partner with LiquidGoldConcept, a women-founded team of experts, who have created a high-fidelity lactation simulator capable of modeling a wide variety of breastfeeding complications. The world’s first realistic  and wearable  breastfeeding training tool for parents, students and medical providers, LiquidGoldConcept’s lactation simulation models simulate a wide range of normal (and abnormal) conditions that include early stage mastitis, engorgement, plugged ducts, as well as nipple damages and fissures.
Read More
2020 in Review: The State of Maternal and Neonatal Health
2020 in Review: The State of Maternal and Neonatal Health

November 04, 2020

Assessing the global status of maternal and neonatal health in 2020 presents a varied, albeit alarming, view of the lives of mothers and newborns around the world. The socioeconomic strain of the COVID-19 pandemic, moreover, has caused upticks in adult and child malnutrition, leading experts to predict a rise in maternal and neonatal mortality this year. 

Read More
New preeclampsia risk-factor checklists to aid health care providers in identifying pregnant women who may benefit from prophylactic low-dose aspirin
New preeclampsia risk-factor checklists to aid health care providers in identifying pregnant women who may benefit from prophylactic low-dose aspirin

August 14, 2020

This past June, the Society for Maternal-Fetal Medicine (SMFM) published in the   American Journal of Obstetrics and Gynecology   a special statement on a collection of two new checklists they created to support health care providers in identifying pregnant women at heightened risk of developing preeclampsia, a major cause of maternal and perinatal morbidity and mortality. 
Read More
News & Updates

Sign up to get the latest on sales, new releases and more …

maternal and newborn health news